Benzothiazole derivatives

Details Benzothiazole derivatives Benzothiazole derivatives

2006-08-15

2006-08-15

McKane, Joseph K. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S103000, C548S161000

Reexamination Certificate

active

07091227

ABSTRACT:
The present invention is directed to a compound of formula (I),racemic-diastereomeric mixtures thereof, optical isomers thereof, prodrugs thereof, isotopes thereof or pharmaceutically-acceptable salts of said compound, isomers, prodrugs and isotopes, wherein the variables are defined herein.The compounds of this invention are useful as inhibitors of serine/threonine and tyrosine kinases. In particular, compounds of this invention are useful as inhibitors of tyrosine kinases that are important in hyperproliferative diseases, especially in cancer and in the process of angiogenesis.

REFERENCES:
patent: 3810988 (1974-05-01), Janiak
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 2002/0123484 (2002-09-01), Das et al.
patent: 566 226 (1995-11-01), None
patent: 1580876 (1980-12-01), None
patent: 57-175189 (1982-10-01), None
patent: 62-187842 (1987-08-01), None
patent: 11-130761 (1999-05-01), None
patent: 11-222431 (1999-08-01), None
patent: WO 91/15495 (1991-10-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 92/21660 (1992-12-01), None
patent: WO 94/03427 (1994-02-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/14808 (1994-07-01), None
patent: WO 97/22596 (1997-06-01), None
patent: WO 97/34876 (1997-09-01), None
patent: WO97/40830 (1997-11-01), None
patent: WO 97/40831 (1997-11-01), None
patent: WO 97/42187 (1997-11-01), None
patent: WO 98/04536 (1998-02-01), None
patent: WO 98/07832 (1998-02-01), None
patent: WO 99/00357 (1999-01-01), None
patent: WO 99/24035 (1999-05-01), None
patent: WO 01/07411 (2001-02-01), None
Duncia et al., 2000, CAS: 133:252423.
Sawhney et al., 1984, CAS:100:139014.
Bhattacharya et al., CAS:113:100536.
Nakrani, A.D. et al., “Manganese(II) complexes of N-phenyl-N′-(6-substituted)benzothiazolylthiocarbamide,”J. Ind. Chem. Soc. 68(9):517-18 (1991).
Sarkis, G.Y. et al., “Cobalt(II), Nickel(II) and copper(II) complexes of some N-benzoyl N′-aryl or heterocyclic substituted thioureas,”J. Iraqi Chem. Soc., 13(1):103-115 (1988).
Singh, G.C., “Studies onN-methyl-N′-2-benzothlazolyl guanidines,”Indian J. Appl. Chem. 31(3-4):117-120 (1968).
Sutoris, V. et al., “Benzothiazole compounds. III. Synthesis and biological activity of substitutedN-(2- benzothiazolyl)ureas and benzothiazolyldihydrouracils,”Chem. Zvesti, 27(6):829-33 (1973).
Weiss, B. et al., “Effects of various amides on a rat brain puromycin-sensitive aminopeptidase and on induced convulsions in mice,”Res. Commun. Psychol., 17(3-4):153-9 (1992).
Bell, F.W. “Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. Synthesis and basic structure-activity relationship studies of PETT analogs,”J. Med. Chem. 38(25):4929-36 (1995).
Bhargava, P.N. et al., “Substituted benzothiazolyl guanidines,”Curr. Sci. 40(6):430-32 (1971).
Bhargava, P.N. et al., “Synthesis of some new substituted benzothiazolyl thiazolidones as potential gungicides,”Curr. Sci. 42(20):717-18 (1973).
Bhargava, P.N. et al., “Synthesis and spectral behaviour of some new (substituted) benzothiazolyl guanidines,”Curr. Sci. 43(2):33-36 (1974).
Bhargava, P.N. et al., “Synthesis of some new benzothiazolylguanidines and their activities,”J. Ind. Chem. Soc. 56(4):377-80 (1979).
Chaudhari, B.R. et al., “Synthesis of some 2-imino-N(6′-substituted benzothiazo-2′-yl)-4-thiazolidinones and their bis-derivatives as antibacterial agents,”Asian. J. Chem. 7(4):832-36 (1995).
Kamala, K. et al., “Synthesis of 2-aroyliminobenzothiazolo[3,2-b]-1,2,4-thiadiazolines,”J. Ind. Chem., 29B(8):778-80 (1990).
Expert Opin. Ther. Pat.8(4): 475-478 (1998).
Achen et al, “Vascular endothetial growth factor D (VEGF-D) is a ligant for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).”PNAS USA95(2): 548-553 (1998).
Aplin et al., “In vitro phosphorylation of the cytoplasmic domain ot the amyloid precursor protein by blycogen synthase kinase-3β,”Journal of Neurochemistry, 67:699-707 (1996).
Armstrong, “Treatment of opportunistic fungal infections,”Clinical Infectious Diseases, 16:1-7 (1993).
Badger et al., “Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function,”The Journal of Pharmacology and Experimental Therapeutics, 279:1453-1461 (1996).
Baeuerie et al., “Function and activation of NF-kappa B in the immune system,”Annual Review of Immunology, 12:141-179 (1994).
Beg et al., “An essential role for NF-kappaB in prreventing TNF-alpha-induced cell death,”Science, 274:782-784 (1996).
Bolen, “Nonreceptor tyrosina protein kinases,”Oncogene8:2025-2931 (1993).
Borthwick et al., “Inhibition of glycogen synthase kinase-3 by insulin cultured human skeletal muscle myoblasts,”Biochemical & Biophysical Research Communications, 210:738-745 (1995).
Brickell, “The p60c-src family of protein-tyrosine kinases: structure, regulation, and function,”Critical Reviews in Oncogenesis, 3:401-406 (1992).
Brown et al.,Regulation of Angiogenesis(ed. L.D. Goldberg and E.M. Rosen), 233-269 (1997).
Buchdunger et al., “Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class,”PNAS USA, 92:2258-2262 (1995).
Courtneidge, “Protein tyrosine kinases, with emphasis on the Src family,”Seminars in Cancer Biology, 5:236-246 (1994).
Cowburn, “Peptide recognition by PTB and PDZ domains,”Curr. Opin. Struct. Biol, 7(6):835-838 (1997).
De Vries et al. “The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor,”Science255:989-991 (1992).
Draetta, “Cdc2 activation: The interplay of cyclin binding and Thr161 phosphorylation,”Trends in Cell Biology, 3:287-289 (1993).
Ducommun et al., “cdc2 phosphorylation is required for its interaction with cyclin,”EMBO Jornal, 10:3311-1119 (1991).
Fanti et al., “Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways,”Cell69:413-423 (1992).
Ferrara et al. “The vascular endothelial growth factor family of polypeptides,”J. Cell. Biochem.47:211-218 (1991).
Ferrara et al., “Vascular endothelial growth factor. Basic biology and clinical implications,” in Regulation of Angiogenesis (ed. L. D. Goldberg and E.M. Rosen), 209-232 (1997).
Ferrara et al., “The biology of vascular entothelial growth factor,”Endocrine Reviews18(1): 4-25 (1997).
Gautier et al., “Dephosphorylation and activation of Xenopus p34cdc2 protein kinase during the cell cycle,”Nature339:626-629 (1989).
Gilbert, “Horizontal integration and cortical dynamics,”Neuron9:1-13 (1992).
Girard et al., “Cyclin A is required for the onset of DNA replication in mammalian fibroblasts,.”Cell, 67:1169-1179 (1991).
Kim et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo,”Nature362:841-844 (1993).
He et al., “The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines,”Journal of Virology, 71:405-411 (1997).
Hosoi et al., “Evidence for cdk5 as a major activity phosphorylating tau proteinin porcine brain extract,”Journal of Biochemistry(Tokyo), 117:741-749 (1995).
Hunter et al., “Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age,”Cell, 79:573-582 (1994).
Jakeman et al., “Developmental expression of binding sit

Affiliated with

Also associated with

Rating

Benzothiazole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzothiazole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzothiazole derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3636662